Galectin-3 in pre-B acute lymphoblastic leukemia
Author(s)
Fei, F
Abdel-Azim, H
Lim, M
Arutyunyan, A
von Itzstein, M
Groffen, J
Heisterkamp, N
Griffith University Author(s)
Year published
2013
Metadata
Show full item recordAbstract
Only 30-40% of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term, disease-free survival and can be considered cured. The remainder will eventually relapse and die from disease progression or other ALL-related consequences. Relapse most frequently originates in the bone marrow (BM),3 where stroma protects ALL cells against drug treatment.Only 30-40% of adult patients with acute lymphoblastic leukemia (ALL) achieve long-term, disease-free survival and can be considered cured. The remainder will eventually relapse and die from disease progression or other ALL-related consequences. Relapse most frequently originates in the bone marrow (BM),3 where stroma protects ALL cells against drug treatment.
View less >
View less >
Journal Title
Leukemia
Volume
27
Issue
12
Subject
Receptors and membrane biology
Clinical sciences
Oncology and carcinogenesis
Oncology and carcinogenesis not elsewhere classified